by TractManager | Mar 29, 2018 | Emerging Technology Report
Bevyxxa is a potent and specific inhibitor of human factor Xa activity that acts by competitively binding to the active site of factor Xa, preventing its ability to convert prothrombin to thrombin. It is the first non-vitamin K antagonist oral anticoagulant (NOAC)...
by TractManager | Mar 29, 2018 | Emerging Technology Report
Tymlos is a synthetic peptide analog of parathyroid hormone-related protein (PTHrP) for the treatment of osteoporosis in postmenopausal women who are at increased risk for fracture or have failed or are intolerant to other available osteoporosis therapies. It is...
by TractManager | Mar 29, 2018 | Precision Therapy Assessment
Health Problem: The prevalence of obesity remains high in the United States. Recent estimates indicate that more than one-third of adults have obesity. Obesity is a serious health concern because it adversely affects mental health and quality of life, and is...
by TractManager | Mar 29, 2018 | Health Technology Assessment
Health Problem: Obesity is a multifaceted condition, involving a combination of factors such as behavior, genetics, medication use, and dietary patterns, as well as community environment, education, and food marketing. Obesity is associated with poorer mental health...
by TractManager | Mar 28, 2018 | Health Technology Assessment
Health Problem: Vulvovaginal atrophy, also known as atrophic vaginitis or genitourinary syndrome of menopause, is a collection of signs and symptoms that are caused by changes to the urogenital tissues due to a decrease in estrogen and other sex steroids. Effects of...
Recent Comments